>Human Cell Expressed
>Rat SEMA4D / Semaphorin 4D Protein (His Tag)
|Catalog||Size (Price)||Quantity||In Stock||Operation||Other Information|
Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D Protein Datasheet
SEMA4D / Semaphorin-4D Protein Price Inquiry ( Available Sizes )
SEMA4D / Semaphorin-4D Protein Product Information
A DNA sequence encoding the rat SEMA4D (Met1-Met712) was expressed, fused with a polyhistidine tag at the C-terminus.
|Expression Host:||Human Cells|
SEMA4D / Semaphorin-4D Protein QC Testing
|Purity:||> 95 % as determined by SDS-PAGE||SDS-PAGE:
SEMA4D / Semaphorin-4D protein
|Endotoxin:||< 1.0 EU per μg of the protein as determined by the LAL method|
|Stability:||Samples are stable for up to twelve months from date of receipt at -70℃|
|Predicted N terminal:||Phe 24|
The recombinant rat SEMA4D comprises 700 amino acids and predicts a molecular mass of 77.8 kDa. The apparent molecular mass of the recombinant protein is approximately 96 kDa in SDS-PAGE under reducing conditions due to glycosylation.
|Formulation:||Lyophilized from sterile PBS, pH7.4.
SEMA4D / Semaphorin-4D Protein Usage Guide
|Storage:||Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.|
|Reconstitution:||A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.|
SEMA4D / Semaphorin-4D Protein Related Products & Topics
|Molecule||Species||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|Syndecan-1/SDC1/CD138||Human||Syndecan-1/SDC1/CD138 Protein, Recombinant||11429-H08H|
|Syndecan-1/SDC1/CD138||Mouse||Syndecan-1/SDC1/CD138 Protein, Recombinant||50641-M08H|
|Syndecan-1/SDC1||Rat||SDC1 / Syndecan-1 / SYND1 Protein, Recombinant||80344-R02H|
|Syndecan-1/SDC1||Rat||SDC1 / Syndecan-1 / SYND1 Protein, Recombinant||80344-R08H|
|Molecule||Application||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|Human Semaphorin 4D/SEMA4D/CD100||WB, ELISA||SEMA4D / CD100 Antibody||11825-MM02|
|Human Semaphorin 4D/SEMA4D/CD100||ELISA||SEMA4D / CD100 Antibody||11825-MM06|
|Human Semaphorin 4D/SEMA4D/CD100||WB, ELISA||SEMA4D / CD100 Antibody||11825-RP01|
|Human Semaphorin 4D/SEMA4D/CD100||WB, ELISA||SEMA4D / CD100 Antibody (Antigen Affinity Purified)||11825-RP02|
|Mouse Semaphorin 4D/SEMA4D/CD100||WB, ELISA||Semaphorin 4D / SEMA4D / CD100 Antibody||50642-RP01|
|Mouse Semaphorin 4D/SEMA4D/CD100||WB, ELISA||Semaphorin 4D / SEMA4D / CD100 Antibody (Antigen Affinity Purified)||50642-RP02|
SEMA4D / Semaphorin-4D Protein Description
Semaphorin-4D, also known as SEMA4D and CD100, is a single-pass type I membrane protein which belongs to the semaphorin family. Semaphorin-4D / SEMA4D contains one Ig-like C2-type (immunoglobulin-like) domain, one PSI domain and one Sema domain. Semaphorin-4D / SEMA4D is strongly expressed in skeletal muscle, peripheral blood lymphocytes, spleen, and thymus and also expressed at lower levels in testes, brain, kidney, small intestine, prostate, heart, placenta, lung and pancreas, but not in colon and liver. Semaphorin-4D / SEMA4D may play a functional role in the immune system, as well as in the nervous system. Induces B-cells to aggregate and improves their viability. Semaphorin-4D / SEMA4D is an axon guidance molecule which is secreted by oligodendrocytes and induces growth cone collapse in the central nervous system. By binding plexin-B1 receptor it functions as an R-Ras GTPase-activating protein (GAP) and repels axon growth cones in both the mature central nervous system. In the immune system, Semaphorin-4D / SEMA4D binds CD72 to activate B cells and dendritic cells. It is involved in oligodendrogenesis during development and during recovery from ischemic injury.
- Masuda,K. et al., 2004, Genes Cells. 9 (9):821-9.
- Duran-Struuck R. et al., 2007, Biol Blood Marrow Transplant. 13 (11): 1294-303.
- Taniguchi Y. et al., 2009, J Neurosci Res. 87 (13): 2833-41.
- Ch'ng E S. et al., 2010, Mol Cancer. 9 :251.